Chordoma is a rare and relentless bone cancer that can occur in people of all ages. The aim of Chordoma UK is to financially support and ensure the future of high-impact research initiatives being carried out by a team of scientists, led by Professor Adrienne Flanagan, Head of The Research Department of Pathology at the UCL Cancer Institute.
The dedicated research team’s primary focus is to undertake ground breaking research over the next 3 years including screening 1000 drugs and compounds against chordoma tumours. This is in order to discover how this cancer can be treated, and develop effective treatments to improve the lives of chordoma patients.
To read more about this fund, please visit the Chordoma UK website
Page last modified on 21 may 13 16:57